Atara Biotherapeutics (ATRA) Reports Q1 Loss, Tops Revenue Estimates

Atara Biotherapeutics (ATRA) came out with a quarterly loss of $0.23 per share versus the Zacks Consensus Estimate of a loss of$ 0.37. This compares to loss of $0.72 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 37.84%. A quarter ago, it was expected that this drug developer would post a loss of$ 0.61 per share when it actually produced a loss of $0.56, delivering a surprise of 8.20%.Over the last four quarters, the company ...